Stock Research: Medpaces

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Medpaces

NSQ:MEDP US58506Q1094
54
  • Value
    18
  • Growth
    99
  • Safety
    Safety
    9
  • Combined
    29
  • Sentiment
    73
  • 360° View
    360° View
    54
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service clinical development services. The company operates in the biotechnology, pharmaceutical, and medical device industries, offering phase I-IV clinical development services, bio-analytical laboratory services, clinical human pharmacology, imaging, and electrocardiography reading support. Their operations are principally based in North America, Europe, and Asia. In the last fiscal year, the company had a market cap of $8988 million, profits of $656 million, revenue of $2109 million, and 5900 employees.

more
Index
NASDAQ
D.J. US Health Care
S&P MIDCAP
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
18 9 8 35
Growth
99 73 97 91
Safety
Safety
9 9 69 77
Sentiment
73 33 100 75
360° View
360° View
54 54 90 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 34 83 16
Opinions Change
50 22 50 50
Pro Holdings
n/a 56 92 92
Market Pulse
100 46 91 78
Sentiment
73 33 100 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
18 9 8 35
Growth
99 73 97 91
Safety Safety
9 9 69 77
Combined
29 29 65 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
55 32 38 67
Price vs. Earnings (P/E)
15 42 30 37
Price vs. Book (P/B)
1 17 3 33
Dividend Yield
1 1 1 1
Value
18 9 8 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
63 67 82 75
Profit Growth
70 33 73 51
Capital Growth
86 78 89 75
Stock Returns
67 59 87 75
Growth
99 73 97 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
100 100 62 100
Refinancing
6 8 3 13
Liquidity
1 1 100 90
Safety Safety
9 9 69 77

Similar Stocks

Discover high‑ranked alternatives to Medpaces and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: